FDA Accepts New Qnexa Petition

November 3rd, 2011 by MorganDowney Leave a reply »

Vivus Inc. announced that the Food and Drug Administration had accepted its New Drug Application for Qnexa™. The FDA expects to have an Advisory Committee hearing in the first quarter of 2012. The proposed labeling includes a contraindication for women of childbearing age. VIVUS, Inc. – FDA Accepts New Drug Application Filing for Qnexa, At the same time, a study was published on Qnexa ™ in 1,267 persons with severe obesity which showed an average weight loss of 14.4% from initial body weight. VIVUS, Inc. – Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment